Deep Intelligent Pharma Files IPO Prospectus Highlighting GPT-4.0 Turbo-Powered Writing-X Platform That Boosts Medical Writing Efficiency by 87%

May 13, 2024 09:26 CST Updated 09:26

Deep Intelligent Pharma

AI-Driven Drug Discovery Platform

Introduction

2024 is hailed as the first year of AI, with various AI application scenarios emerging one after another, Deep Intelligent PharmaAt the 2024 DIA China Annual Meeting ExhibitionWill showcase its revolutionary AI products, including Writing-X and Translation-X, which will help regulatory affairs and medical writing professionals find ways to improve efficiency.Liberate繁琐重复的工作，让Deep Thinking Happen. ToWriting-X Product inApplication of Safety Narrative Report WritingFor example,This tool can complete complex report writing at the minute level, improving work efficiency by 87% compared to traditional methods.

From May 17 to 19, 2024, the global pharmaceutical industry's focus will be on the Suzhou International Expo Center, where the annual DIA (Drug Information Association) Global Annual Meeting and Exhibition will take place. At the "Deep Intelligent Pharma" booth located at the entrance of Hall C3,Deep Intelligent Pharma, dedicated to becoming a pioneer in the implementation of AIGC in the pharmaceutical field, will present its latest AI products, including Writing-X and Translation-X.

Among them, Writing-X is a medical writing tool deeply optimized using GPT 4.0 Turbo technology and the database accumulated over the years by Deep Intelligent Pharma. This tool can complete complex medical document writing at the minute level, improving work efficiency by 87% compared to traditional methods.

Deep Intelligent Pharma CEO Ms. Li Xing will attend in person, inviting all partners to explore how AI is leading the revolution in registration affairs and clinical development efficiency while enjoying a selection of fine coffees. Interested users can also experience it on-site. We have prepared 2,000 cups of coffee with 15 different flavors from around the world to ensure that every participant can experience innovation in a relaxed and enjoyable atmosphere.

Note: A total of 2000 cups of coffee, including Starbucks® Blonde Espresso, Starbucks® Reserve™ Blend, Starbucks® Espresso Roast, Rajero Coffee, Forte Rich Coffee, Ristretto Coffee, Ristretto Intenso Coffee, Decaffeinated Coffee, Finido Coffee, Intense Coffee, Caramel Flavored Coffee, Hazelnut Flavored Coffee, Vanilla Flavored Coffee, Mild Bianco Coffee, Intense Bianco Coffee.......

Writing-X

AIGC High-Efficiency Professional Writing Platform

Equipped with GPT4 Turbo Medical Writing Large Model

Writing X is a medical writing product independently developed by Deep Intelligent Pharma. It is powered by the GPT-4 Turbo large model, officially licensed by Microsoft, and further optimized by Deep Intelligent Pharma’s AI scientists using accumulated data from years of medical writing experience. The product has successfully helped multiple clients reduce costs and improve efficiency. It can generate reports in minutes, improving efficiency by 87% compared to traditional manual writing.

Taking Safety Narrative report writing as an example, the traditional model faces numerous challenges:

1. Low writing efficiency

Writing staff need to read a large amount of scattered and complex reference materials. Fatigue from prolonged reading of multiple references reduces the efficiency of writing staff, and accuracy also decreases. Therefore, it usually requires multiple writing staff to complete the writing periodically.

2. Difficult to standardize

The writing of Narrative often needs to follow the norms of policies, industries, and enterprises for written expression. The writing styles and expression abilities of different writers are difficult to standardize in a short period.

3. Information Omission and Errors

Inexperienced writers' lack of expertise in professional knowledge, corporate standards, and writing norms may lead to deviations, misinterpretations, and omissions during the data analysis process. Therefore, inexperienced writers require extensive learning and quality control from experienced writers.

Writing-X Product inSafety NarativeReport automatic writing saves 87% of the time compared to traditional writing methods, with an accuracy rate of up to 96%.

A client in China is simultaneously facing multiple CSR writing projects with a tight schedule and heavy workload. However, the reference document formats are not fixed, and the data accuracy requirements are high. By helping the client build a dedicated WritingX system,Achieved project delivery within 2 days, with an 87% increase in efficiency compared to the customer's previous working model. The direct output accuracy rate is 85%, and after intelligent QC proofreading with the product's built-in features, the accuracy rate reaches 96%.Greatly liberates repetitive labor, allowing customers' scientists more time for in-depth thinking and analysis of deeper issues.

Regarding the efficiency calculation method: Manual writing + QC takes 40 minutes, while AI writing + QC takes only 5 minutes. Thus: (Current efficiency - Original efficiency) ÷ Original efficiency × 100%, which is 35/40*100% = 87%.

Regarding the calculation method of accuracy: One Narrative contains 28 descriptive items, of which AI accurately wrote 24 items, with an accuracy rate of (24/28)*100% = 85%. Intelligent QC made changes to 3 cases, achieving an accuracy of 96%.

Scan to get the PDF document of this case

Deep Intelligent Pharma

AIGC Pioneer in Pharmaceutical Applications

Translation-X，Writing-X

— THE END —

Deep Intelligent Pharma was founded in 2017 and operates simultaneously in Singapore, China, and Japan, with paid-in registered capital exceeding 100 million RMB. It is committed to using artificial intelligence technology to reduce costs and improve efficiency across the entire pharmaceutical development chain ("efficiency" first). The company focuses on text intelligence and has independently developed generative artificial intelligence (AIGC)-native automatic writing (Writing-X) and automatic translation platforms (Translation-X), covering all document types in pharmaceutical development. It also provides industry-leading efficient translation and writing services for registration documents. Additionally, the company has independently developed an AIGC-enhanced intelligent management platform, including EDC, pharmacovigilance, eTMF, registration document management systems, e-CTD, human genetic resource management systems, SSU, and more. Deep Intelligent Pharma is currently serving over 700 pharmaceutical companies and CRO clients globally, with a market share in translation services that is far ahead.